Unrelated Donor Transplant for Malignant and Non-Malignant Disorders

Lymphoma Clinical Trial

Official title:

Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01050439
• Other study ID #: AAAB3095
• Secondary ID: CHNY-02-516
• Status: Terminated
• Phase: Phase 2
• First received: June 3, 2008
• Last updated: April 14, 2015
• Start date: November 2002
• Est. completion date: April 2011

Study information

• Verified date: April 2015
• Source: Columbia University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Unrelated matched donor (cord blood, bone marrow or peripheral blood) allogeneic stem cell transplantation (UDAlloSCT) with either myeloablative or reduced intensity conditioning will be well tolerated and result in a high degree of engraftment in patients with selected malignant and non malignant disorders.

Description:

This is a non-randomized study to determine the tolerability and degree of engraftment of unrelated matched donor allogeneic stem cell transplantation with either myeloablative or reduced intensity conditioning in patients with selected malignant and non malignant disorders. Patients will receive one of either full intensity or reduced intensity regimen based on the patient's disease status, organ function and performance and determined by the PI.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: April 2011
• Est. primary completion date: April 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A to 55 Years

Eligibility

Inclusion Criteria:

• Adequate renal function defined as: serum creatinine 2.0 x normal, or creatinine clearance or radioisotope GFR > 40 ml/min/m2 or > 40 ml/min/1.73 m2 or an equivalent GFR as determined by the institutional normal range.

• Adequate liver function defined as: total bilirubin < 2.5 x normal; or SGOT (AST) or SGPT (ALT) < 5.0 x normal.

• Adequate cardiac function defined as: shortening fraction of > 25% by echocardiogram, or ejection fraction of > 40% by radionuclide angiogram or echocardiogram.

• Adequate pulmonary function defined as: DLCO > 35% by pulmonary function test. For children who are uncooperative, no evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% in room air.

• Diseases:

• CML (CP, AP or BC)

• AML/MDS/JCML

• ALL

• Lymphoma (Hodgkin's and non-Hodgkin's)

• Non-malignant disorders

• Bone Marrow Failure Syndromes: Patients with the following diagnoses are eligible:

• Severe Aplastic Anemia:

• Fanconi Anemia

• Severe Congenital Neutropenia (Kostmann's Syndrome)

• Amegakaryocytic Thrombocytopenia

• Diamond-Blackfan Anemia

• Infantile Osteopetrosis

• Schwachman-Diamond Syndrome

• Dyskeratosis Congenita

• Other bone marrow failure syndromes at discretion of Principal Investigator

• Immunodeficiencies:

• SCIDS, all subtypes

• Combined Immunodeficiency Syndrome

• Wiskott-Aldrich syndrome

• Chronic Granulomatous Disease

• Chediak-Higashi Syndrome

• Leukocyte Adhesion Deficiency

• Other immunodeficiencies at discretion of Principal Investigator

• Inborn Errors of Metabolism (IEOM):

• Transplant is recommended for the following disorders: Hurler syndrome (L-iduronidase deficiency, MPS-I), Maroteaux-Lamy syndrome (galactosamine-4-sulfatase deficiency, MP VI), Sly syndrome (glucuronidase deficiency, MPS-VII), Globoid cell Leukodystrophy (galactocerebrosidasedeficiency), Metachromatic leukodystrophy (arylsulfatase A deficiency), Childhood-onset X-linked adrenoleukodystrophy (X-ALD), Fucosidosis (fucosidase deficiency), Mannosidosis, Aspartylglucosaminuria, Niemann-Pick Disease Type B (acid sphingomyelinase deficiency), Gaucher disease (glucocerebrosidase deficiency) Type I (non neuropathic), Other diagnoses may be considered at the discretion of the Principal Investigator

• For X-ALD patients greater than 5 years of age, IQ > 80 is required. For other patients greater than 5 years of age, IQ > 70 is required.

• For patients less than 5 years of age, the developmental quotient or clinical neurodevelopmental examination should demonstrate potential for stabilization at a level of functioning where continuous life support (e.g. mechanical ventilation) would not be predicted to be required in the year following transplantation.

• Histiocytosis:

• Hemophagocytic Lymphohistiocytosis (HLH)

• Familial Erythrophagocytic Lymphohistiocytosis

• Langerhans Cell Histiocytosis

• Malignant Histiocytosis

• Other Malignant and non-malignant diseases: Other malignant and non-malignant diseases not listed above may be eligible if deemed appropriate by the Principal Investigator.

Exclusion Criteria:

• Women who are pregnant and/or breast feeding are ineligible

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bone Marrow Failure Syndromes
• Hemoglobinuria, Paroxysmal
• Histiocytosis
• Immunodeficiencies
• Immunologic Deficiency Syndromes
• Leukemia
• Lymphoma
• Pancytopenia

Intervention

Procedure:
• UDAlloSCT
unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)

Other:
• Therapy
Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))

Locations

Country	Name	City	State
United States	Columbia University Medical Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Columbia University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of toxicity related to myeloablative therapy	To determine the safety and toxicity of myeloablative therapy (TBI + Melphalan) and unrelated donor alloSCT in selected patients with malignant and non-malignant disorders.	Up to 10 years from start of study	Yes
Secondary	Incidence of toxicity related to reduced intensity therapy	To determine the safety and toxicity of reduced intensity therapy (Fludarabine, Busulfan, and Alemtuzumab (FBA) and unrelated donor alloSCT in selected patients with malignant and non malignant disorders	Up to 10 years from start of study	Yes
Secondary	Percentage of donor chimerism	To quantitate the percentage of donor chimerism following both myeloablative and reduced intensity conditioning and unrelated donor alloSCT in selected patients with malignant and non-malignant disorders.	Up to 10 years from start of study	No
Secondary	Prevalence of progression free survival	To estimate the progression free survival (PFS), if applicable, event free survival (EFS) and overall survival (OS) following unrelated donor alloSCT in selected patients with malignant and non malignant disorders.	Up to 10 years from start of study	No